The deal is subject to HSR waiting period expiration and tender of a majority of shares. Monitor for any competing bids during the go-shop period and regulatory developments. The expected close by end of 2026 provides a clear timeline for arbitrageurs.
Price Chart
Executive Summary
Pacira BioSciences has entered into a definitive agreement to be acquired by Viatris for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion. The transaction will be structured as a tender offer followed by a second-step merger, and Pacira's board unanimously recommends that shareholders tender their shares.
Key Financial Metrics
Key Facts
- Viatris to acquire Pacira for $36.50 per share in cash, aggregate equity value of $1.65 billion
- Pacira generated approximately $746 million in total revenue and approximately $177 million in adjusted EBITDA in LTM ended June 30, 2026
- Transaction unanimously approved by both companies' boards; expected to close by end of 2026
- Pacira shareholders to receive $36.50 per share in cash; stock will be delisted from Nasdaq
- Termination fee of $62 million payable by Pacira under certain circumstances
Financial Impact
All-cash acquisition at $36.50/share, aggregate equity value of $1.65 billion; represents a significant premium to pre-announcement trading levels
Risk Factors
- Regulatory approval risk under HSR Act could delay or block the transaction
- Risk of competing superior proposal triggering termination fee
- Integration risk for Viatris in combining Pacira's commercial operations
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-114571 |
| Document: tm2627240d2_ex99-1.htm | 0001104659-26-114571 |
| Document: tm2627240d2_8k.htm | 0001104659-26-114571 |
| Document: 0001104659-26-114571-index-headers.html | 0001104659-26-114571 |
| Document: 0001104659-26-114571-index.html | 0001104659-26-114571 |
| Document: 0001104659-26-114571.txt | 0001104659-26-114571 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | SC 13D/A | $36.40 | awaiting T+20 | — | $36.40 (−0.00%) |
Oct 8, 2026 18d ago | SC TO-C | $36.31 | awaiting T+20 | — | $36.40 (+0.25%) |
Oct 8, 2026 19d ago | 144 | $36.39 | awaiting T+20 | — | $36.40 (+0.03%) |
Oct 8, 2026 19d ago | 8-K | $36.39 | awaiting T+20 | — | $36.40 (+0.03%) |
Oct 8, 2026 19d ago | SC TO-C | $36.39 | awaiting T+20 | — | $36.40 (+0.03%) |
Aug 6, 2026 11w ago | Press Release | $25.58 $26.60 | ▲ +3.99% | ▲ +3.39% | $36.40 (+42.30%) |
Jul 22, 2026 13w ago | Press Release | $25.59 $24.36 | ▼ −4.81% | ▼ −7.70% | $36.40 (+42.24%) |
Jun 30, 2026 17w ago | 8-K | $25.37 $26.47 | ▲ +4.34% | ▲ +5.36% | $36.40 (+43.48%) |
Jun 12, 2026 19w ago | Insider Cluster | $22.74 $25.54 | ▲ +12.31% | ▲ +13.06% | $36.40 (+60.07%) |
Jun 4, 2026 20w ago | DEFA14A | $22.75 $25.59 | ▲ +12.48% | ▲ +10.62% | $36.40 (+60.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers